A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Clinical trial NCT07221188 · RECRUITING

Trial details

NCT number: NCT07221188
Sponsor: GlaxoSmithKline
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-alcoholic Fatty Liver Disease

Start date: 2025-12-12
Primary completion: 2028-03-24
Enrollment: 1250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.